Using Night-time Blood Pressure to Treat Hypertension

Not Applicable

Completed

• Conditions: Hypertension
• Interventions: Behavioral: treatment of BP by using night-time BP; Behavioral: treatment of BP by using daytime BP

• Registration Number: NCT05031637
• Lead Sponsor: Chinese University of Hong Kong

Brief Summary

Objectives: To examine the feasibility of conducting night-time home blood pressure(BP) monitoring (during sleep) and titration of medications in the evening. This will provide data for sample size calculation for the main trial, which will examine whether night-time BP is a better target than conventional daytime BP for hypertension management.

Hypothesis to be tested: night-time home BP monitoring(HBPM) and evening drug titration are acceptable to patients; and future main trial is feasible in terms of recruitment/dropout rate/medication adherence.

Design and subjects: This pilot randomized-controlled trial will recruit 78 patients with nocturnal hypertension (asleep systolic BP 120mmHg on ambulatory blood pressure monitoring(ABPM)). They will be allocated in 1:1 ratio to have their medication titrated in the evening according to night HBPM (Experimental group) or in the morning according to daytime HBPM (control group) respectively.

Instruments: ABPM/HBPM. Interventions: titration of the dose(s) of anti-hypertensive medications in the evening according to night HBPM (experimental group) and in the morning according to daytime HBPM (control group) every 4 weeks.

Main outcome measures: ABPM at baseline and at 6 months Data analysis and expected results: The rate of recruitment/dropout and adherence to night HBPM will be presented. The feasibility of HBPM will be assessed by the patients' adherence to HBPM and by patients' interviews. ANCOVA will be used to evaluate whether titration of medication can normalize BP levels. We expect patients to have a high adherence rate and that titration of evening doses of medications will better improve night-time BP on ABPM.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-08-29
• Study First Submitted QC: 2021-09-01
• Study First Posted: 2021-09-02
• Study Start: 2022-05-01
• Primary Completion: 2024-01-31
• Study Completion: 2024-02-28
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-30
• Last Update Posted: 2024-05-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

• diagnosed hypertension (HT) from clinical records
• nocturnal HT (night-time systolic blood pressure (SBP) during sleep ≥120 mmHg) and stage I hypertension (daytime SBP = 135-159mmHg)

Read More

Exclusion Criteria

• patients with atrial fibrillation (many home blood pressure (BP) machines are not validated in these patients and these patients have greater BP variability)
• daytime office systolic BP ≥180 mmHg or diastolic BP ≥120 mmHg (regardless of nocturnal BP) because these patients need urgent BP treatment and it is not known if medications given in the evening are equally effective
• patients with known obstructive sleep apnoea because the night-time BP of these patients is predominately affected by the sleep apnoea
• patients with known stroke, ischemic heart disease, heart failure, kidney failure, peripheral vascular disease and diabetes mellitus because their daytime BP targets will be different
• dementia or psychiatric illness that impairs patients' ability to perform home blood pressure monitoring (HBPM) by themselves
• patients with end-stage malignancies
• nocturnal worker, because they will have a reverse BP pattern to other participants
• patients who sleep after 2am or wake up before 4am because these patients will not be asleep during night HBPM
• patients receiving ≥3 BP medications at maximal tolerated doses because there is little space for drug titration and these patients may have secondary HT representing another disease spectrum
• patients receiving anti-coagulants because ABPM can induce significant bruises (during repeated cuff inflations) in these patients.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
treatment by night-time BP	treatment of BP by using night-time BP	titrate drug treatment in the evening against night home blood pressure monitoring (HBPM) SBP (aiming SBP of \<120 mmHg; intervention group)
treatment by daytime BP	treatment of BP by using daytime BP	Usual care - titrate drug treatment in the morning against HBPM SBP (aiming SBP of \<135 mmHg; control group)

Primary Outcome Measures

Name	Time	Method
dropout rate	0 month to 24 month (end of trial)	number of participants drop-out from each arm
the rate of recruitment	0 month to 18 month (anticipated recruitment period)	number of participants recruited per month during recruitment period
feasibility of repeated ambulatory blood pressure monitoring (ABPM)	0 month to 24 month (end of trial)	the proportion of patients finished both ABPM
feasibility of home blood pressure (BP) measurement	0 month to 24 month (end of trial)	the proportion of patients who can measure nocturnal BP successfully

Secondary Outcome Measures

Name	Time	Method
serum creatinine level	taken at 0 month and 6 month	an assessment for renal function (the higher value suggest poorer renal function)
systolic BP (SBP) / diastolic BP (DBP) on ABPM	taken at 0 month and 6 month for each patient	Mean daytime/night-time/24-hour SBP/DBP
microalbuminuria	taken at 0 month and 6 month	the presence of microalbuminuria suggest renal damage
lipid profile	taken at 0 month and 6 month	low-density lipoprotein (LDL), high-density lipoprotein (HDL), Triglyceride (TG), total cholesterol (TC)

Trial Locations

Locations (1)

School of public health and primary care; 🇭🇰 Hong Kong, Hong Kong